Austar Lifesciences Past Earnings Performance
Past criteria checks 0/6
Austar Lifesciences's earnings have been declining at an average annual rate of -4.3%, while the Life Sciences industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 13.5% per year.
Key information
-4.3%
Earnings growth rate
-4.1%
EPS growth rate
Life Sciences Industry Growth | 41.4% |
Revenue growth rate | 13.5% |
Return on equity | -2.9% |
Net Margin | -1.3% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Investors Aren't Buying Austar Lifesciences Limited's (HKG:6118) Revenues
Aug 28We Think Shareholders May Want To Consider A Review Of Austar Lifesciences Limited's (HKG:6118) CEO Compensation Package
May 24Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive
Apr 18Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?
Mar 28Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump
Feb 12Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues
Dec 22We Think Austar Lifesciences (HKG:6118) Has A Fair Chunk Of Debt
Sep 28Here's Why Austar Lifesciences (HKG:6118) Has A Meaningful Debt Burden
Mar 31Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Sep 19Is Austar Lifesciences (HKG:6118) A Risky Investment?
Apr 06Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet
Oct 24With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting
Sep 27If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late
May 31Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly
Mar 31Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?
Mar 01Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Feb 01Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?
Jan 11Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly
Dec 21Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?
Dec 07Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like
Nov 23Revenue & Expenses Breakdown
How Austar Lifesciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 1,545 | -19 | 276 | 51 |
31 Mar 24 | 1,654 | -26 | 304 | 53 |
31 Dec 23 | 1,764 | -33 | 333 | 55 |
30 Jun 23 | 2,089 | 2 | 343 | 64 |
31 Mar 23 | 2,159 | 45 | 327 | 67 |
31 Dec 22 | 2,157 | 104 | 303 | 70 |
30 Sep 22 | 2,246 | 96 | 307 | 71 |
30 Jun 22 | 2,264 | 105 | 304 | 72 |
31 Mar 22 | 2,139 | 191 | 304 | 69 |
31 Dec 21 | 2,015 | 277 | 304 | 66 |
30 Sep 21 | 1,824 | 258 | 304 | 59 |
30 Jun 21 | 1,633 | 238 | 304 | 52 |
31 Mar 21 | 1,465 | 136 | 281 | 50 |
31 Dec 20 | 1,296 | 33 | 259 | 48 |
30 Sep 20 | 1,193 | 25 | 253 | 47 |
30 Jun 20 | 1,089 | 17 | 246 | 45 |
31 Mar 20 | 1,069 | 12 | 248 | 44 |
31 Dec 19 | 1,049 | 8 | 251 | 43 |
30 Sep 19 | 1,007 | 8 | 234 | 39 |
30 Jun 19 | 966 | 8 | 216 | 36 |
31 Mar 19 | 891 | 4 | 200 | 33 |
31 Dec 18 | 817 | 0 | 183 | 30 |
30 Sep 18 | 724 | -16 | 182 | 29 |
30 Jun 18 | 631 | -33 | 182 | 28 |
31 Mar 18 | 589 | -43 | 177 | 27 |
31 Dec 17 | 547 | -54 | 171 | 26 |
30 Sep 17 | 587 | -43 | 160 | 27 |
30 Jun 17 | 628 | -32 | 149 | 28 |
31 Mar 17 | 650 | -25 | 150 | 30 |
31 Dec 16 | 673 | -19 | 151 | 32 |
30 Sep 16 | 648 | -17 | 146 | 32 |
30 Jun 16 | 624 | -16 | 141 | 31 |
31 Mar 16 | 626 | -5 | 134 | 29 |
31 Dec 15 | 628 | 6 | 127 | 27 |
30 Sep 15 | 640 | 24 | 122 | 26 |
30 Jun 15 | 652 | 43 | 118 | 26 |
31 Mar 15 | 666 | 54 | 120 | 25 |
31 Dec 14 | 680 | 65 | 122 | 24 |
30 Sep 14 | 676 | 58 | 128 | 24 |
30 Jun 14 | 672 | 51 | 133 | 24 |
31 Mar 14 | 689 | 52 | 126 | 24 |
31 Dec 13 | 705 | 54 | 120 | 24 |
Quality Earnings: 6118 is currently unprofitable.
Growing Profit Margin: 6118 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6118 is unprofitable, and losses have increased over the past 5 years at a rate of 4.3% per year.
Accelerating Growth: Unable to compare 6118's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6118 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (0.7%).
Return on Equity
High ROE: 6118 has a negative Return on Equity (-2.85%), as it is currently unprofitable.